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Glycaemic control and the risk of mortality in elderly
type 2 diabetic patients (ZODIAC-20)
K. J. J. van Hateren,1 G. W. D. Landman,1,2 N. Kleefstra,1,3,4 I. Drion,1 K. H. Groenier,5
S. T. Houweling,3,5,6 H. J. G. Bilo1,2,4
Introduction
In a recent response to a meta-analysis of the Collab-
orators on Trials of Lowering Glucose (CONTROL)
Group, the differences between patients with type 2
diabetes mellitus (T2DM) of short and long duration
were emphasised (1,2). Based on the heterogeneous
results of four large randomised-controlled trials, it
seems that intensive glucose control is only beneficial
in those with diabetes of short duration (3–6). A
meta-analysis, published in 2006, already showed that
the beneficial effects of improved glycaemic control
decreased with longer diabetes duration and with
increasing age (7). Unfortunately, there are no clini-
cal data on the macrovascular and microvascular
consequences of (intensive) glucose control in adults
older than 75 years. Although guidelines recommend
applying less stringent targets to frail older adults
and those with limited life expectancy, the level of
evidence of this advice is low and mainly based on
expert opinion (8). We aimed to explore the rela-
tionship between HbA1c and (cardiovascular) mortal-
ity, and the role of diabetes duration in this
relationship, in a prospectively designed cohort of
elderly patients (> 75 years) with T2DM.
Patients and methods
Study population
This study is part of the Zwolle Outpatient Diabetes
project Integrating Available Care (ZODIAC) study;
the design and details of which have been presented
elsewhere (9). In this study, general practitioners are
assisted by hospital-based diabetes specialist nurses
in their care of patients with T2DM. At baseline,
patients with a very short life expectancy (including
SUMMARY
Aims: Studies on macrovascular consequences of glucose control in elderly
patients (> 75 years) with type 2 diabetes mellitus (T2DM) are lacking. The pres-
ent study aimed to investigate the relationship between HbA1c and mortality in this
specific population. Methods: Between 1998 and 1999, 374 primary care patients
with T2DM aged older than 75 years participated in the Zwolle Outpatient Diabe-
tes project Integrating Available Care study, a prospective observational study.
Early 2009, data on mortality were collected. Updated means for annually mea-
sured HbA1c values were calculated after a follow-up time of 10 years. Updated
mean HbA1c was used as a time-dependent covariate in a Cox proportional hazard
model. Main outcome measures were all-cause and cardiovascular disease (CVD)
mortality. Analyses were performed in strata according to diabetes duration (< 5,
5–11 and ‡ 11 years). Results: In the group with a diabetes duration < 5 years,
an increase of 1% in the updated mean HbA1c level was associated with an
increase in all-cause and CVD mortality risk of 51% (95% CI 17–95%) and 72%
(95% CI 19–148%), respectively. Glycaemic control was not related to mortality
for patients with a diabetes duration ‡ 5 years. Conclusion: Poor glycaemic con-
trol is related to increased all-cause and CVD mortality in patients > 75 years with
T2DM of short duration (< 5 years). Discussion: Because of the observational
study design, our results should be interpreted with caution. Nevertheless, they are
suggestive that improving glycaemic control may be beneficial in elderly patients
with T2DM, especially in those with recently diagnosed T2DM. Randomised-con-
trolled trials are necessary to investigate whether this holds true.
What’s known
The beneficial effects of improved glycaemic control
decrease with longer diabetes duration and with
increasing age. However, there are no clinical data
on the macrovascular and microvascular
consequences of (intensive) glucose control in the
very old (patients > 75 years).
What’s new
Higher levels of HbA1c are related to increased all-
cause and CVD mortality in diabetic patients aged
older than 75 years, but only in those with
diabetes of short duration (< 5 years). Randomised-
controlled trials are necessary to investigate
whether improving glycaemic control in specific
elderly diabetic populations, for example patients
with newly diagnosed T2DM, may be beneficial.
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patients with active cancer) or insufficient cognitive
abilities were excluded (5%). Four patients were
excluded because of insufficient baseline data. Nearly
90% (n = 1357) of the remaining patients agreed to
participate. For the present study, we selected all
patients aged older than 75 years (n = 374).
Data collection
Baseline data were collected in 1998 and 1999, and
consisted of a full medical history including macro-
vascular complications, medication use and tobacco
consumption. Patients were considered to have mac-
rovascular complications when they had a history of
angina pectoris, myocardial infarction, percutaneous
transluminal coronary angioplasty, coronary artery
bypass grafting, stroke or transient ischaemic attack.
Laboratory and physical assessment data such as
HbA1c, lipid profile, serum creatinine, the urinary
albumin-to-creatinine ratio, blood pressure, weight
and height were collected annually. An updated
mean of annually measured HbA1c was calculated for
each individual from baseline to the end of the fol-
low-up period by averaging the baseline values with
the mean annual values. For example, at 1 year the
updated mean HbA1c is the average of the baseline
and 1 year values, and at 3 years it is the average of
baseline, 1, 2 and 3 year values. This technique is
similar to the one used in the United Kingdom Pro-
spective Diabetes Study (UKPDS) (10).
Clinical endpoints
We examined two clinical endpoints in this study:
all-cause and cardiovascular disease (CVD) mortality.
Early 2009, the vital status and cause of death were
retrieved from records maintained by the hospital
and the general practitioners. The causes of death
were coded according to The International Classifica-
tion of Diseases, 9th revision (ICD-9).
Statistical analyses
Continuous variables are presented as mean (± stan-
dard deviation) for normally distributed values and
as median (interquartile range) for non-normally dis-
tributed values. Normality was evaluated using Q–Q
plots. Nominal variables are presented as the total
number of patients (percentage). A Cox proportional
hazard model was used to investigate the relationship
between the updated mean HbA1c, as a time-depen-
dent covariate, and mortality with and without
adjustment for selected confounders. We used two
different models. In model 1, only age and gender
were taken into account as possible confounders. In
model 2, we adjusted for the following variables: age,
gender, smoking (yes or no), BMI, duration of dia-
betes, serum creatinine, macrovascular complications
(yes or no), albuminuria (yes or no), systolic blood
pressure, total cholesterol–HDL ratio and use of
insulin (yes or no). Analyses were repeated in strata
according to diabetes duration. The diabetes dura-
tion variable at baseline was categorised into tertiles:
< 5 (n = 111), 5–11 (n = 139) and ‡ 11 years
(n = 124). In order to estimate the possible impli-
cations of higher HbA1c levels on mortality, we
calculated the population attributable risk per cent
(PAR%) of HbA1c levels ‡ 7% for all-cause and car-
diovascular mortality (11). In our analyses PAR%
can be interpreted as the percentage by which mor-
tality rates could be reduced if all patients would
have had HbA1c levels < 7%. The assumption of
proportional hazards was checked by inspecting the
Schoenfeld residual plots for the baseline predictor
variables. All analyses were performed with SPSS
version 15.0.1 (SPSS Inc., Chicago, IL).
Ethics statement
The ZODIAC study and the informed consent proce-
dure were approved by the local medical ethics com-
mittee. Informed consent was obtained from all
patients.
Results
Baseline characteristics of our study population are
presented in Table 1. Approximately one-third of our
study population was men. Median age (interquartile
range) was 80 (78–83) years and median diabetes
duration was 8 (4–13) years. Patients with a diabetes
duration ‡ 11 years (tertile 3) had lower mean body
mass index and were more often smokers compared
with patients with shorter diabetes duration. The
number of patients treated with only a diet was the
highest in the group with a diabetes duration
< 5 years (tertile 1); also, use of insulin was the lowest
in this group compared with patients with longer dia-
betes duration. After a follow-up time of 10 years, 304
of 374 patients (81%) had died, of which 127 deaths
(42%) were attributable to cardiovascular causes.
Analyses overall group
In multivariate analyses (model 2), an increase of 1%
in HbA1c led to an increase in CVD mortality risk by
26% (95% CI 6–49%). The unadjusted hazard ratio,
and the age- and gender-adjusted one, were not rele-
vantly different. The relationship with all-cause mor-
tality was not significant in both models.
Analyses stratified according to diabetes
duration (Table 2)
In the group with a diabetes duration < 5 years
(tertile 1), the level of HbA1c as a continuous variable
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was positively related to both all-cause and CVD mor-
tality. In multivariate analyses, an increase of 1% in
HbA1c was associated with an increase in all-cause
and CVD mortality risk of 51% (95% CI 17–95%)
and 72% (95% CI 19–148%), respectively. All results
for patients with a diabetes duration ‡ 5 years were
not significant.
Population attributable risk per cent
The PAR% of HbA1c levels ‡ 7% for all-cause mor-
tality in patients with diabetes of short duration was
23% (95% CI 2–36%). For CVD mortality the
PAR% was 39% (95% CI 17–48%). Again, all results
for patients with a diabetes duration ‡ 5 years were
not significant.















Age (years) 80 (78–83) 80 (78–83) 80 (77–82) 80 (78–84) 0.887
Male sex 130 (34.8) 34 (30.6) 57 (41.0) 39 (31.5) 0.148
Body mass index (kg ⁄m2) 27.8 (4.4) 28.6 (4.4) 28.0 (4.3) 26.9 (4.2) 0.012
Duration of T2DM (years) 8 (4–13) 2 (1–3) 7 (6–9) 16 (13–20) –
Systolic blood pressure (mm Hg) 155.7 (24.7) 153.1 (24.3) 156.8 (24.9) 156.7 (24.9) 0.416
Current smoking 33 (8.8) 4 (3.7) 11 (8.0) 18 (14.8) 0.011
HbA1c (%) 7.4 (1.2) 7.3 (1.3) 7.5 (1.1) 7.4 (1.2) 0.292
Albuminuria present 206 (55.1) 53 (47.7) 84 (60.4) 69 (55.6) 0.133
Cholesterol–HDL ratio 4.9 (1.6) 5.2 (1.7) 4.8 (1.6) 4.7 (1.5) 0.099
Serum creatinine (lmol ⁄ l) 98 (86–115) 95 (82–111) 99 (87–123) 98 (87–111) 0.165
Macrovascular complications present 162 (43.3) 45 (40.5) 62 (44.6) 55 (44.4) 0.780
Treatment T2DM
diet 40 (10.7) 19 (17.1) 13 (9.4) 8 (6.5) 0.025
oral glucose lowering agents 265 (70.9) 85 (76.6) 102 (73.4) 78 (62.9) 0.050
insulin 79 (21.1) 7 (6.3) 32 (23.0) 40 (32.3) <0.001
Receiving antihypertensive treatment 231 (61.8) 71 (65.1) 82 (59.4) 78 (63.9) 0.610
Receiving lipid lowering treatment 17 (4.5) 5 (4.6) 8 (5.8) 4 (3.3) 0.627
Data are means (± SD), medians (interquartile range) or n (%). One-way ANOVA, chi-square, or Kruskal–Wallis test was used where
appropriate to test for differences between groups.
Table 2 Analyses stratified according to diabetes duration. Hazard ratios and the 95% confidence intervals of HbA1c,












All-cause Unadjusted 1.24 (1.01–1.52) 1.01 (0.83–1.24) 0.99 (0.82–1.20)
Model 1* 1.27 (1.03–1.55) 1.04 (0.85–1.26) 1.03 (0.84–1.26)
Model 2 1.51 (1.17–1.95) 1.04 (0.84–1.28) 1.05 (0.85–1.30)
CVD Unadjusted 1.35 (1.00–1.81) 1.17 (0.87–1.57) 1.19 (0.91–1.55)
Model 1* 1.37 (1.02–1.84) 1.19 (0.99–1.15) 1.28 (0.98–1.68)
Model 2 1.72 (1.19–2.48) 1.18 (0.87–1.60) 1.16 (0.86–1.58)
*Adjusted for age and gender. Adjusted for age, gender, smoking (yes or no), BMI, duration of diabetes, serum creatinine level,
macrovascular complications (yes or no), albuminuria (yes or no), systolic blood pressure, total cholesterol–HDL ratio and use of insulin
(yes or no).
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All analyses were repeated with only the baseline
HbA1c value as variable of interest (data not shown).
Results did not relevantly change. The proportional
hazards assumptions were met for all analyses.
Discussion
Poor glycaemic control is related to increased all-
cause and CVD mortality in patients with T2DM aged
over 75 years, but only in those with diabetes of short
duration. In the lowest tertile (duration < 5 years),
the all-cause mortality risk was 51% higher for every
1% increase in HbA1c. For CVD mortality, the
increase in mortality risk was even 72%.
To our knowledge, the relationship between HbA1c
and mortality in elderly patients with T2DM has not
been described before. In previous observational and
intervention studies elderly patients were either not
included or subanalyses were not performed for this
specific population. More recently, a large retrospec-
tive observational study showed that there seems to
be a U-shaped association between HbA1c and mor-
tality (12). Although an estimated 16% of the study
population was aged over 75 years, no subanalyses
were performed.
It is important to emphasise that the associations
found between HbA1c and mortality in this study do
not imply causality. Because of the observational nat-
ure of our study, we can only speculate about the
underlying mechanisms. Firstly, poor glycaemic con-
trol itself may indeed affect mortality risk in elderly
patients with recently diagnosed diabetes. The heter-
ogeneous results of four large randomised-controlled
trials in younger patients already suggested that
intensive glucose control may only be beneficial with
regard to mortality in those with diabetes of short
duration (1,4–6,13). Secondly, it may be possible that
our results are influenced by confounders we did not
adjust for. For example, the results for all-cause mor-
tality may be confounded by co-morbidities such as
cancer or infectious diseases. In order to reduce the
impact of reverse causality we performed additional
analyses for the overall group, in which we excluded
the deaths in the first year of follow-up. This did not
relevantly change the results.
Besides its observational design, there are other rea-
sons why our results should be interpreted with cau-
tion. Firstly, our study cohort is rather small and only
comprises 374 elderly patients with T2DM. As we also
stratified our cohort into tertiles, the number in these
tertiles is even smaller. Secondly, the heterogeneous
health status of elderly patients makes it more difficult
to identify the implications of our results for clinical
practice. However, additional analyses revealed that
for patients with a diabetes duration < 5 years, the
all-cause mortality rate could theoretically have been
lowered by 23% if all patients had had HbA1c levels
< 7%. An important strength of our study is its pro-
spective design. Other strengths of our study are the
high number of deaths after 10 years follow-up, the
use of the updated mean method and the number of
variables we adjusted for in our model.
Although our study is the first study linking higher
levels of HbA1c to increased mortality in elderly
patients with recently diagnosed diabetes, we do not
recommend aiming for intensive glycaemic control
for all subjects in this specific patient category. Inten-
sive control may also lead to an increased risk of
hypoglycaemia causing possible adverse events such
as fall accidents and fractures. Physicians caring for
older patients should take co-morbidity, frailty and
estimated life expectancy into account when setting
treatment goals for individual patients. Confirmation
of our results in other cohorts would be interesting,
because if confirmed, randomised-controlled trials
are necessary to investigate whether improving gly-
caemic control in specific elderly diabetic popula-
tions, for example patients with newly diagnosed
T2DM, may be beneficial.
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